Real-World Experience of Bevacizumab as First-Line Treatment for Ovarian Cancer: The GINECO ENCOURAGE Cohort of 468 French Patients

Real-World Experience of Bevacizumab as First-Line Treatment for Ovarian Cancer: The GINECO ENCOURAGE Cohort of 468 French Patients

Introduction: Bevacizumab-containing therapy is considered a standard-of-care front-line option for stage IIIB–IV ovarian cancer based on results of randomized phase 3 trials. The multicenter non-interventional ENCOURAGE prospective cohort study assessed treatment administration and outcomes in the...

Full description

Bibliographic Details
Main Authors: Dominique Berton, Anne Floquet, Willy Lescaut, Gabriel Baron, Marie-Christine Kaminsky, Philippe Toussaint, Rémy Largillier, Aude-Marie Savoye, Jérôme Alexandre, Catherine Delbaldo, Emmanuelle Malaurie, Hugues Barletta, Claire Bosacki, Claire Garnier-Tixidre, Philippe Follana, Hortense Laharie-Mineur, Charles Briac Levache, Bruno Valenza, Agnès Dechartres, Delphine Mollon-Grange, Frédéric Selle
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-09-01
Series:Frontiers in Pharmacology
Subjects:
bevacizumab
ovarian cancer
routine clinical practice
monitoring
progression-free survival
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2021.711813/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2021.711813/full

Similar Items